You didn't mention ARRY's collaboration with AMGN on a diabetes drug (in Phase II, I believe.) Does that mean that you ascribe no value to that program? What about ARRY's proprietary molecules. They certainly have enough cash to develop at least one or two of them, don't you think?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.